KaydedilenlerDerginizi ekleyin

Dergiler / Annals of Medical Research / 2020 / Cilt: 27 - Sayı: 2

The role of PET/CT in determining egfr mutation and ALK rearrangement in patients with lung adenocarcinoma

Ahmet YANARATEŞ
Emine BUDAK
Sayfa
634–640
Yayın Tarihi
2022-10-12
DOI
—
🏛️Bu makalenin bibliyografik verileri ve tam metin bağlantısı DergiPark üzerinden sağlanmıştır.
DergiPark Kaydı ↗
✨

Yapay Zeka Hızlı Bakış & Çıkarımlar

AI Insight
⚡ TL;DR(1 Cümlede Hızlı Çıkarım)

No statistically significant differences were found between the ALK+ and ALK- group in terms of age, sex,cigarette smoking status, tumor stage, or PET parameters.Conclusion: Our study results suggest that a low SUVmax value in lung adenocarcinomas is associated with EGFR mutation, althoughthe diagnostic efficacy is not high.

📌 3 Maddede Bu Makale

🎯
Amaç & Hipotez:Aim: The aim of the present study is to evaluate the role of tumor FDG uptake in a non-invasive method and the use of positronemission tomography / computed tomography (PET/CT) in estimating epidermal growth factor receptor (EGFR) mutations andanaplastic lymphoma kinase (ALK) rearrangements in cases of adenocarcinoma of the lung.Material and Methods: A total of 115 patients with the diagnosis of an adenocarcinoma of the lung that underwent F-18 FDG PET/CTfor staging and whose EGFR mutation and ALK rearrangement status were analyzed were retrospectively analyzed.
📊
Temel Bulgular & Veri:The associationof the PET parameters (SUVmax, SUVmean, MTV and TLG) of primary tumor with the molecular profile was analyzed.Results: EGFR mutations (EGFR+ group) and ALK rearrangements (ALK+ group) were found in 15 (13%) and 10 (8.7%) of 115 patients;and 90 patients (78.3%) had no EGFR mutation or ALK rearrangement (EGFR/ALK-).
💡
Sonuç & Katkı:No statistically significant differences were found between the ALK+ and ALK- group in terms of age, sex,cigarette smoking status, tumor stage, or PET parameters.Conclusion: Our study results suggest that a low SUVmax value in lung adenocarcinomas is associated with EGFR mutation, althoughthe diagnostic efficacy is not high.
🔬Tür:Araştırma Makalesi
📍Kapsam:Genişletilmiş Akademik Örneklem
⚙️Değişkenler:Alan Parametreleri

Abstract

Aim: The aim of the present study is to evaluate the role of tumor FDG uptake in a non-invasive method and the use of positronemission tomography / computed tomography (PET/CT) in estimating epidermal growth factor receptor (EGFR) mutations andanaplastic lymphoma kinase (ALK) rearrangements in cases of adenocarcinoma of the lung.Material and Methods: A total of 115 patients with the diagnosis of an adenocarcinoma of the lung that underwent F-18 FDG PET/CTfor staging and whose EGFR mutation and ALK rearrangement status were analyzed were retrospectively analyzed. The associationof the PET parameters (SUVmax, SUVmean, MTV and TLG) of primary tumor with the molecular profile was analyzed.Results: EGFR mutations (EGFR+ group) and ALK rearrangements (ALK+ group) were found in 15 (13%) and 10 (8.7%) of 115 patients;and 90 patients (78.3%) had no EGFR mutation or ALK rearrangement (EGFR/ALK-). EGFR mutations were found to be significantlyhigher among the never-smoked group (p=0.009). No significant association was identified between the SUVmean, MTV and TLGvalues and EGFR mutations; however, patients with a low SUVmax value were found to have a significantly higher rate of EGFRmutation (p=0.034). No statistically significant differences were found between the ALK+ and ALK- group in terms of age, sex,cigarette smoking status, tumor stage, or PET parameters.Conclusion: Our study results suggest that a low SUVmax value in lung adenocarcinomas is associated with EGFR mutation, althoughthe diagnostic efficacy is not high.

🔖

Bu Makaleye Atıf Yap

YANARATEŞ, A., BUDAK, E. (2022). The role of PET/CT in determining egfr mutation and ALK rearrangement in patients with lung adenocarcinoma. Annals of Medical Research, Cilt: 27 - Sayı: 2, 634–640. https://ajindex.com/articles/446352

📄 Tam Metin PDF Okuyucu

📄

PDF görüntüleyici hazırlanıyor...

Kaynakça (11)

  1. Dela Cruz CS, Tanoue LT, Matthay RA. Lung cancer: Epidemiology, etiology, and prevention. Clin Chest Med 2011;32:605-44
  2. Mitsudomi T, Yatabe Y. Mutations of the epidermal growth factor receptor gene and related genes as determinants of epidermal growth factor receptor tyrosine kinase inhibitors sensitivity in lung cancer. Cancer Sci 2007;98:1817-24
  3. Shaw AT, Engelman JA. ALK in lung cancer: Past, present, and future. J ClinOncol.2013;31:1105-11
  4. Lynch TJ, Bell DW, Sordella R, Gurubhagavatula S, Okimoto RA, Brannigan BW, et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 2004;350:2129-39
  5. Paez JG, Jänne PA, Lee JC, Tracy S, Greulich H, Gabriel S, et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 2004;304:1497-500
  6. Shaw AT, Kim DW, Nakagawa K, et al. Crizotinib versus chemotherapy in advanced ALK-positive lung cancer. N Engl J Med 2013;368:2385-94
  7. Lindeman NI, Cagle PT, Beasley MB, Chitale DA, Dacic S, Giaccone G, et al. Molecular testing guideline for selection of lung cancer patients for EGFR and ALK tyrosine kinase inhibitors: guideline from the College of American Pathologists, International Association for the Study of Lung Cancer, and Association for Molecular Pathology. J ThoracOncol 2013;8:823-59
  8. Leighl NB, Rekhtman N, Biermann WA, Huang J, MinoKenudson M, Ramalingam SS, et al. Molecular testing for selection of patients with lung cancer for epidermal growth factor receptor and anaplastic lymphoma kinase tyrosine kinase inhibitors: American Society of Clinical Oncology endorsement of the College of American Pathologists/international association for the study of lung cancer/ association for molecular pathology guideline. J ClinOncol 2014;32:3673-9
  9. Makinoshima H, Takita M, Matsumoto S, et al. Epidermal growth factor receptor (EGFR) signaling regulates global metabolic pathways in EGFR-mutated lung adenocarcinoma. J Biol Chem 2014;289:20813– 23
  10. De Rosa V, Iommelli F, Monti M, et al. Reversal of Warburg effect and reactivation of oxidative Phosphorylation by differential inhibition of EGFR signaling pathways in non-small cell lung cancer. Clin Cancer Res 2015;21:5110-20
  11. Mak RH, Digumarthy SR, Muzikansky A, Engelman JA, Shepard JA, Choi NC, et al. Role of 18F-fluorodeoxyglucose positron emission tomography in predicting epidermal growth factor receptor mutations in